Literature DB >> 10971392

In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.

A Bolognesi1, L Polito, P L Tazzari, R M Lemoli, C Lubelli, M Fogli, L Boon, M de Boer, F Stirpe.   

Abstract

Immunotoxins specific for the CD80 and CD86 antigens were prepared by linking three type 1 ribosome-inactivating proteins (RIPs), namely bouganin, gelonin and saporin-S6, to the monoclonal antibodies M24 (anti-CD80) and 1G10 (anti-CD86). These immunotoxins showed a specific cytotoxicity for the CD80/CD86-expressing cell lines Raji and L428. The immunotoxins inhibited protein synthesis by target cells with IC50s (concentration causing 50% inhibition) ranging from 0.25 to 192 pmol/l as RIPs. The anti-CD80 immunotoxins appeared 1-2 log more toxic for target cells than the anti-CD86 ones. Immunotoxins containing saporin and bouganin induced apoptosis of target cells. The toxicity for bone marrow haemopoietic progenitors of these conjugates was also evaluated. Bouganin and related immunotoxins at concentrations up to 100 nmol/l did not significantly affect the recovery of committed progenitors or of more primitive cells. The saporin-containing immunotoxins at concentrations >/= 1 nmol/l showed some toxicity on colony-forming unit cells (CFU-C). The expression of the CD80 and CD86 molecules is prevalently restricted to antigen-presenting cells and is also strong on Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Present results suggest that immunotoxins targeting type 1 ribosome-inactivating proteins to these antigens could be considered and further studied for the therapy of Hodgkin's disease or other CD80/CD86-expressing tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971392     DOI: 10.1046/j.1365-2141.2000.02193.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.

Authors:  Andrea M Patterson; Saghar Kaabinejadian; Curtis P McMurtrey; Wilfried Bardet; Ken W Jackson; Rosemary E Zuna; Sanam Husain; Gregory P Adams; Glen MacDonald; Rachelle L Dillon; Harold Ames; Rico Buchli; Oriana E Hawkins; Jon A Weidanz; William H Hildebrand
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

Review 3.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

4.  The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).

Authors:  Sonali M Smith; Heiko Schöder; Jeffrey L Johnson; Sin-Ho Jung; Nancy L Bartlett; Bruce D Cheson
Journal:  Leuk Lymphoma       Date:  2013-01-04

Review 5.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

Review 6.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.

Authors:  Dmitrij Hristodorov; Radoslav Mladenov; Michael Huhn; Stefan Barth; Theo Thepen
Journal:  Toxins (Basel)       Date:  2012-09-14       Impact factor: 4.546

8.  Immunotoxins: a review of their use in cancer treatment.

Authors:  G Aruna
Journal:  J Stem Cells Regen Med       Date:  2006-12-26

Review 9.  Saporin-S6: a useful tool in cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Daniele Mercatelli; Maria Giulia Battelli; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2013-10-07       Impact factor: 4.546

10.  High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.

Authors:  Massimo Bortolotti; Andrea Bolognesi; Maria Giulia Battelli; Letizia Polito
Journal:  Toxins (Basel)       Date:  2016-06-21       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.